Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-11,577
Closed -$644K 1372
2021
Q3
$644K Buy
11,577
+1,679
+17% +$93.3K 0.04% 729
2021
Q2
$537K Buy
9,898
+2,387
+32% +$131K 0.03% 878
2021
Q1
$421K Buy
7,511
+912
+14% +$45.5K 0.02% 974
2020
Q4
$287K Buy
6,599
+1,200
+22% +$47.2K 0.02% 1067
2020
Q3
$210K Buy
+5,399
New +$237K 0.01% 1340
2019
Q1
Sell
-8,314
Closed -$393K 1176
2018
Q4
$393K Buy
8,314
+1,786
+27% +$107K 0.01% 561
2018
Q3
$487K Buy
+6,528
New +$450K 0.01% 637

Other funds holding SRDX

Winton Group's SRDX Position: Q4 2021 in Review

Winton Group sold out of Surmodics (SRDX) in Q4 2021, closing a stake of 11,577 shares — an estimated $644K sold.

Winton Group first reported a position in SRDX in Q3 2018 and held it in 7 quarters. The position peaked at $644K in Q3 2021. 148 funds tracked by Wall St. Rank hold SRDX as of Q4 2021.

  • Winton Group reported no remaining Surmodics position as of Q4 2021 after selling out during the quarter.
  • Winton Group sold 11,577 Surmodics shares in Q4 2021, an estimated $644K.
  • Winton Group first reported a position in Surmodics in Q3 2018 and held it in 7 quarters.
  • Winton Group's Surmodics position peaked at $644K in Q3 2021.
  • 148 funds tracked by Wall St. Rank held Surmodics as of Q4 2021.

Based on Winton Group's 13F filing for Q4 2021, filed 10 Feb 2022.